



Markets Best Report : PharmaPoint Meningococcal Vaccines US,France and Germany Drug Market 2022

*New Markets Research Report Added In MarketsResearchReports.Biz Reports Database
PharmaPoint Meningococcal Vaccines U S,France and Germany Drug Market 2022*

ALBANY, NY, July 4, 2013 /EINPresswire.com/ -- GlobalData has released its new Country report, PharmaPoint: Meningococcal Vaccines United States Drug Forecast and Market Analysis to 2022. Meningococcal disease is an acute infection caused by the gram-negative bacterium *Neisseria meningitidis*. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines. Currently, tetravalent conjugate vaccines, such as Sanofis Menactra and Novartis Menveo, account for the vast majority of global sales, with the US adolescent market being the key target segment. GlobalData expects growth in the meningococcal vaccines market to be primarily driven by the launch of serotype B vaccines, which address a critical unmet need in the treatment landscape. Vaccines that better protect infants and/or provide a longer duration of immunity also have an opportunity to seize market share during 2012-2022.

To Read The Complete Report with TOC : <http://www.marketresearchreports.biz/analysis-details/pharmapoint-meningococcal-vaccines-united-states-drug-forecast-and-market-analysis-to-2022>

GlobalData has released its new Country report, PharmaPoint: Meningococcal Vaccines France Drug Forecast and Market Analysis to 2022. Meningococcal disease is an acute infection caused by the gram-negative bacterium *Neisseria meningitidis*. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines. Currently, tetravalent conjugate vaccines, such as Sanofis Menactra and Novartis Menveo, account for the vast majority of global sales, with the US adolescent market being the key target segment. GlobalData expects growth in the meningococcal vaccines market to be primarily driven by the launch of serotype B vaccines, which address a critical unmet need in the treatment landscape. Vaccines that better protect infants and/or provide a longer duration of immunity also have an opportunity to seize market share during 2012-2022.

To Read The Complete Report with TOC : <http://www.marketresearchreports.biz/analysis-details/pharmapoint-meningococcal-vaccines-france-drug-forecast-and-market-analysis-to-2022>

GlobalData does not expect relative patient share to change within the MenC conjugate space because Nuron Biotech's Meningitec, Novartis Menjugate kit, and Baxters NeisVac-C all possess similar clinical profiles and price points. The MenC conjugate patient share is largely determined by

prescriber preference in France and therefore is not expected to change drastically during the forecast period. The French government has expressed disappointment with the low coverage rates of its MenC immunization program and is expected to renew efforts to expand vaccine use (Stahl et al., 2013). In general, the sales potential in France is derived from the immunization recommendations, which largely determine vaccine usage.

GlobalData has released its new Country report, PharmaPoint: Meningococcal Vaccines Germany Drug Forecast and Market Analysis to 2022. Meningococcal disease is an acute infection caused by the gram-negative bacterium *Neisseria meningitidis*. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines. Currently, tetravalent conjugate vaccines, such as Sanofis Menactra and Novartis Menveo, account for the vast majority of global sales, with the US adolescent market being the key target segment. GlobalData expects growth in the meningococcal vaccines market to be primarily driven by the launch of serotype B vaccines, which address a critical unmet need in the treatment landscape. Vaccines that better protect infants and/or provide a longer duration of immunity also have an opportunity to seize market share during 2012-2022.

To Read The Complete Report with TOC : <http://www.marketresearchreports.biz/analysis-details/pharmapoint-meningococcal-vaccines-germany-drug-forecast-and-market-analysis-to-2022>

GlobalData predicts that relative patient share for the three MenC conjugate vaccines will remain unchanged for the duration of the forecast period because Nuron Biotech's Meningitec, Novartis Menjugate kit, and Baxters NeisVac-C possess nearly identical clinical profiles and price points. The MenC conjugate patient share is largely determined by prescriber preference in Germany and therefore is not expected to change drastically during the forecast period.

Scope

- Overview of Meningococcal Vaccines including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in Germany including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in Germany from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting Germany Meningococcal Vaccines market.

M/s Sheela
Marketresearchreports
+1-518-618-1030
email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2016 IPD Group, Inc. All Right Reserved.